Patents by Inventor Osvaldo Reyes Acosta
Osvaldo Reyes Acosta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10434137Abstract: The present invention describes a method to inhibit replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, more precisely the proteins forming the intermediate cytoskeletal filaments, wherein the the proteins are vimentin and/or keratin-10. The replication of the virus is inhibited in human cells by intervening in the structure of these proteins. The present invention is also related to the use of agents, including peptides and/or interfering RNA and/or lipidic compounds, the agents producing a negative modulation or alteration of the cytoskeleton to prevent or to treat the HIV infection.Type: GrantFiled: November 17, 2015Date of Patent: October 8, 2019Assignee: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Celia Berta Fernandez Ortega, Anna Caridys Ramírez Suarez, Dionne Casillas Casanova, Taimi Emelia Paneque Guerrero, Raimundo Ubieta Gomez, Marta Dubed Echevarria, Leonor Margarita Navea Leyva, Lila Rosa Castellanos Serra, Carlos Antonio Duarte Cano, Viviana Falcon Cama, Osvaldo Reyes Acosta
-
Patent number: 9896482Abstract: The present invention discloses structurally constrained synthetic peptides that have been optimized for the formation of a beta hairpin structure. Said peptides are able to inhibit or attenuate Dengue virus (DENV) infections. The invention also discloses pharmaceutical compositions containing these synthetic peptides, which are useful for the prevention and/or treatment of DENV-caused infections. Likewise, the invention disclosed a method for treating infections caused by this virus.Type: GrantFiled: February 26, 2015Date of Patent: February 20, 2018Assignee: Centro de Ingenieria Genética y BiotechnologiaInventors: Glay Chinea Santiago, Vivian Huerta Galindo, Alejandro Miguel Martín Dunn, Hilda Elisa Garay Pérez, Osvaldo Reyes Acosta, Viviana Falcón Cama, Dianne Pupo Gómez, Alexis Yero Díaz, Gabriel Jesús Márquez Perera, Mónica Sarría Núñez, Osmany Guirola Cruz, Rocío Garateix Suárez, Karen Alvarez Pérez, Sonia González Blanco, Mariela Vázquez Castillo, Luis Javier González López
-
Publication number: 20170152290Abstract: The present invention discloses structurally constrained synthetic peptides that have been optimized for the formation of a beta hairpin structure. Said peptides are able to inhibit or attenuate Dengue virus (DENV) infections. The invention also discloses pharmaceutical compositions containing these synthetic peptides, which are useful for the prevention and/or treatment of DENV-caused infections. Likewise, the invention disclosed a method for treating infections caused by this virus.Type: ApplicationFiled: February 26, 2015Publication date: June 1, 2017Inventors: Glay CHINEA SANTIAGO, Vivian HUERTA GALINDO, Alejandro Miguel MARTÍN DUNN, Hilda Elisa GARAY PÉREZ, Osvaldo REYES ACOSTA, Viviana FALCÓN CAMA, Dianne PUPO GÓMEZ, Alexis YERO DÍAZ, Gabriel Jesús MÁRQUEZ PERERA, Mónica SARRÍA NÚÑEZ, Osmany GUIROLA CRUZ, Rocío GARATEIX SUÁREZ, Karen ALVAREZ PÉREZ, Sonia GONZÁLEZ BLANCO, Mariela VÁZQUEZ CASTILLO, Luis Javier GONZÁLEZ LÓPEZ
-
Patent number: 9375459Abstract: The present invention comprises cyclic peptides bearing antitumor and antiangiogenic properties, as well as their corresponding pharmaceutically-suitable salts and also pharmaceutical compositions containing it. These cyclic peptides are used to prepare medicines for human and/or veterinary therapeutics, and additionally in diagnosis. These compounds can be used to detect, monitor and/or control a range of cellular proliferation-related disorders, such as oncological diseases and undesired angiogenesis. Moreover, they can be included as part of controlled release systems, and used more precisely in the field of nanobiotechnology, either because of their self-assembly capacity or as part of other systems.Type: GrantFiled: March 21, 2012Date of Patent: June 28, 2016Assignee: CENTRO DE INGENIERIA GENETICA BIOTECNOLGIAInventors: María del Carmen Abrahantes Pérez, Glay Chinea Santiago, Eduardo Martínez Diaz, Hilda Elisa Garay Pérez, Osvaldo Reyes Acosta, Ernesto Lopez Mola, Cruz Matilde Lopez Abad, Sonia Gonzalez Blanco
-
Patent number: 9364524Abstract: A pharmaceutical composition using natural gonadotropin—releasing hormone (GnRH), and/or some of its mimetic peptides, indistinctly bound by its amino or carboxyl extremes to a carrier molecule; in one case by its carboxyl extreme and in the other case by the amino terminal extreme, thus eliciting a faster and more potent immunological response against the endogenous GnRH hormone. This finally leads to the ablation of the GnRH and consequently of the rest of the involved hormones in the stream GnRH/LH-FSH/Testosterone-(estrogens). An advantage of this formulation consists on facilitating the exposition to the immune system of a greater number of epitopes of the GnRH or its mimetics, minimizing thus the steric hindrance produced by the carriers.Type: GrantFiled: March 19, 2015Date of Patent: June 14, 2016Assignee: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Jesus Arturo Junco Barranco, Osvaldo Reyes Acosta, Eddy Emilio Bover Fuentes, Franklin Fuentes Aguilar, Eulogio Pimentel Vazquez, Roberto Basulto Baker, Gerardo Enrique Guillen Nieto, Yovisleidys Lopez Saez, Hilda Elisa Garay Perez, Lesvia Calzada Aguilera, Maria Castro Santana, Niurka Oneysi Arteaga More, Luis Alberto Aguero Barrocal
-
Publication number: 20160129073Abstract: The present invention describes a method to inhibit replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, more precisely the proteins forming the intermediate cytoskeletal filaments, wherein the said proteins are vimentin and/or keratin-la The replication of the virus is inhibited in human cells by intervening in the structure of these proteins. The present invention is also related to the use of agents, which comprise peptides and/or interfering RNA and/or lipidic compounds, said agents producing a negative modulation or alteration of the cytoskeleton to prevent or to treat the HIV infection. The invention provides means and methods for altering the cytoskeleton/filament structure of cells, as a result of which the infection of human cells by HIV is disturbed and can even be completely inhibited. The cytoskeleton is altered by reducing the amount of vimentin and/or keratin (e.g.Type: ApplicationFiled: November 17, 2015Publication date: May 12, 2016Inventors: Celia Berta Fernandez Ortega, Anna Caridys Ramírez Suarez, Dionne Casillas Casanova, Taimi Emelia Paneque Guerrero, Raimundo Ubieta Gomez, Marta Dubed Echevarria, Leonor Margarita Navea Leyva, Lila Rosa Castellanos Serra, Carlos Antonio Duarte Cano, Viviana Falcon Cama, Osvaldo Reyes Acosta
-
Publication number: 20160106810Abstract: The present invention describes a method to inhibit replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, more precisely the proteins forming the intermediate cytoskeletal filaments, wherein the said proteins are vimentin and/or keratin-10. The replication of the virus is inhibited in human cells by intervening in the structure of these proteins. The present invention is also related to the use of agents, which comprise peptides and/or interfering RNA and/or lipidic compounds, said agents producing a negative modulation or alteration of the cytoskeleton to prevent or to treat the HIV infection. The invention provides means and methods for altering the cytoskeleton/filament structure of cells, as a result of which the infection of human cells by HIV is disturbed and can even be completely inhibited. The cytoskeleton is altered by reducing the amount of vimentin and/or keratin (e.g.Type: ApplicationFiled: November 17, 2015Publication date: April 21, 2016Inventors: Celia Berta Fernandez Ortega, Anna Caridys Ramírez Suarez, Dionne Casillas Casanova, Taimi Emelia Paneque Guerrero, Raimundo Ubieta Gomez, Marta Dubed Echevarria, Leonor Margarita Navea Leyva, Lila Rosa Castellanos Serra, Carlos Antonio Duarte Cano, Viviana Falcon Cama, Osvaldo Reyes Acosta
-
Publication number: 20160108404Abstract: The present invention describes a method to inhibit replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, more precisely the proteins forming the intermediate cytoskeletal filaments, wherein the said proteins are vimentin and/or keratin-10. The replication of the virus is inhibited in human cells by intervening in the structure of these proteins. The present invention is also related to the use of agents, which comprise peptides and/or interfering RNA and/or lipidic compounds, said agents producing a negative modulation or alteration of the cytoskeleton to prevent or to treat the HIV infection. The invention provides means and methods for altering the cytoskeleton/filament structure of cells, as a result of which the infection of human cells by HIV is disturbed and can even be completely inhibited. The cytoskeleton is altered by reducing the amount of vimentin and/or keratin (e.g.Type: ApplicationFiled: November 17, 2015Publication date: April 21, 2016Inventors: Celia Berta Fernandez Ortega, Anna Caridys Ramírez Suarez, Dionne Casillas Casanova, Taimi Emelia Paneque Guerrero, Raimundo Ubieta Gomez, Marta Dubed Echevarria, Leonor Margarita Navea Leyva, Lila Rosa Castellanos Serra, Carlos Antonio Duarte Cano, Viviana Falcon Cama, Osvaldo Reyes Acosta
-
Patent number: 9205128Abstract: The present invention describes a method to inhibit replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, more precisely the proteins forming the intermediate cytoskeletal filaments, wherein the said proteins are vimentin and/or keratin-10. The replication of the virus is inhibited in human cells by intervening in the structure of these proteins. The present invention is also related to the use of agents, which comprise peptides and/or interfering RNA and/or lipidic compounds, said agents producing a negative modulation or alteration of the cytoskeleton to prevent or to treat the HIV infection. The invention provides means and methods for altering the cytoskeleton/filament structure of cells, as a result of which the infection of human cells by HIV is disturbed and can even be completely inhibited. The cytoskeleton is altered by reducing the amount of vimentin and/or keratin (e.g.Type: GrantFiled: April 1, 2011Date of Patent: December 8, 2015Assignee: CENTRO DE INGENIERIA GENETICA Y BIOTECHNOLOGIAInventors: Celia Berta Fernandez Ortega, Anna Caridys Ramírez Suárez, Dionne Casillas Casanova, Taimi Emelia Paneque Guerrero, Raimundo Ubieta Gómez, Marta Dubed Echevarria, Leonor Margarita Navea Leyva, Lila Rosa Castellanos Serra, Carlos Antonio Duarte Cano, Viviana Falcón Cama, Osvaldo Reyes Acosta
-
Patent number: 9145554Abstract: This invention describes a method for treating cancer by increasing the nuclear localization of the COMMD1 protein, which is associated with decreasing or blocking the proliferation of the cancer cell. The invention is also related to the use of agents that increase nuclear localization of the COMMD1 protein, in the manufacture of a medicament for cancer therapy. These agents can be peptides or proteins, among other compounds. The invention is also related to the optimization of a peptide, coming from the sequence HARIKPTFRRLKWKKYKGKFW, to increase the nuclear localization of the protein COMMD, and thus, to increase the antitumor effect of this peptide.Type: GrantFiled: November 8, 2013Date of Patent: September 29, 2015Assignee: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Maribel Guerra Valespi, Julio Raul Fernandez Masso, Alexis Musacchio Lasa, Jeovanis Gil Valdes, Osvaldo Reyes Acosta, Brizaida Maylin Oliva Arguelles
-
Publication number: 20150190491Abstract: A pharmaceutical composition using natural gonadotropin—releasing hormone (GnRH), and/or some of its mimetic peptides, indistinctly bound by its amino or carboxyl extremes to a carrier molecule; in one case by its carboxyl extreme and in the other case by the amino terminal extreme, thus eliciting a faster and more potent immunological response against the endogenous GnRH hormone. This finally leads to the ablation of the GnRH and consequently of the rest of the involved hormones in the stream GnRH/LH-FSH/Testosterone-(estrogens). An advantage of this formulation consists on facilitating the exposition to the immune system of a greater number of epitopes of the GnRH or its mimetics, minimizing thus the steric hindrance produced by the carriers.Type: ApplicationFiled: March 19, 2015Publication date: July 9, 2015Inventors: Jesus Arturo Junco Barranco, Osvaldo Reyes Acosta, Eddy Emilio Bover Fuentes, Franklin Fuentes Aguilar, Eulogio Pimentel Vazquez, Roberto Basulto Baker, Gerardo Enrique Guillen Nieto, Yovisleidys Lopez Saez, Hilda Elisa Garay Perez, Lesvia Calzada Aguilera, Maria Castro Santana, Niurka Oneysi Arteaga More, Luis Alberto Aguero Barrocal
-
Patent number: 8999931Abstract: A pharmaceutical composition using natural gonadotropin-releasing hormone (GnRH), and/or some of its mimetic peptides, indistinctly bound by its amino or carboxyl extremes to a carrier molecule; in one case by its carboxyl extreme and in the other case by the amino terminal extreme, thus eliciting a faster and more potent immunological response against the endogenous GnRH hormone. This finally leads to the ablation of the GnRH and consequently of the rest of the involved hormones in the stream GnRH/LH-FSH/Testosterone-(estrogens). An advantage of this formulation consists on facilitating the exposition to the immune system of a greater number of epitopes of the GnRH or its mimetics, minimizing thus the steric hindrance produced by the carriers.Type: GrantFiled: September 30, 2009Date of Patent: April 7, 2015Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Jesus Arturo Junco Barranco, Osvaldo Reyes Acosta, Eddy Emilio Bover Fuentes, Franklin Fuentes Aguilar, Eulogio Pimentel Vazquez, Roberto Basulto Baker, Gerardo Enrique Guillen Nieto, Yovisleidys Lopez Saez, Hilda Elisa Garay Perez, Lesvia Calzada Aguilera, Maria Castro Santana, Niurka Oneysi Arteaga More, Luis Alberto Aguero Barrocal
-
Publication number: 20140206621Abstract: This invention describes a method for treating cancer by increasing the nuclear localization of the COMMD1 protein, which is associated with decreasing or blocking the proliferation of the cancer cell. The invention is also related to the use of agents that increase nuclear localization of the COMMD1 protein, in the manufacture of a medicament for cancer therapy. These agents can be peptides or proteins, among other compounds. The invention is also related to the optimization of a peptide, coming from the sequence HARIKPTFRRLKWKKYKGKFW, to increase the nuclear localization of the protein COMMD, and thus, to increase the antitumor effect of this peptide.Type: ApplicationFiled: November 8, 2013Publication date: July 24, 2014Applicant: CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍAInventors: Maribel Guerra Vallespi, Julio Raúl Fernández Massó, Alexis Musacchio Lasa, Jeovanis Gil Valdés, Osvaldo Reyes Acosta, Brizaida Maylin Oliva Argüelles
-
Patent number: 8729226Abstract: This invention describes a method for treating cancer by increasing the nuclear localization of the COMMD1 protein, which is associated with decreasing or blocking the proliferation of the cancer cell. The invention is also related to the use of agents that increase nuclear localization of the COMMD1 protein, in the manufacture of a medicament for cancer therapy. These agents can be peptides or proteins, among other compounds. The invention is also related to the optimization of a peptide, coming from the sequence HARIKPTFRRLKWKKYKGKFW, to increase the nuclear localization of the protein COMMD, and thus, to increase the antitumor effect of this peptide.Type: GrantFiled: May 31, 2011Date of Patent: May 20, 2014Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Maribel Guerra Vallespi, Julio Raúl Fernández Massó, Alexis Musacchio Lasa, Jeovanis Gil Valdés, Osvaldo Reyes Acosta, Brizaida Maylin Oliva Argüelles
-
Publication number: 20140112976Abstract: The present invention comprises cyclic peptides bearing antitumor and antiangiogenic properties, as well as their corresponding pharmaceutically-suitable salts and also pharmaceutical compositions containing it. These cyclic peptides are used to prepare medicines for human and/or veterinary therapeutics, and additionally in diagnosis. These compounds can be used to detect, monitor and/or control a range of cellular proliferation-related disorders, such as oncological diseases and undesired angiogenesis. Moreover, they can be included as part of controlled release systems, and used more precisely in the field of nanobiotechnology, either because of their self-assembly capacity or as part of other systems.Type: ApplicationFiled: March 21, 2012Publication date: April 24, 2014Applicant: CENTRO DE INGENIERIA GENETICA BIOTECNOLOGIAInventors: María del Carmen Abrahantes Pérez, Glay Chinea Santiago, Eduardo Martínez Díaz, Hilda Elisa Garay Perez, Osvaldo Reyes Acosta, Ernesto Lopez Mola, Cruz Matilde Lopez Abad, Sonia Gonzalez Blanco
-
Patent number: 8673313Abstract: The present invention relates to use of a new cell penetrating peptides (CPP) and in particular to the region 32-51 of protein Limulus antilipopolisacárido (LALF) and its analogous. This invention refers to compositions containing these peptides associated to biomolecules with therapeutics properties. This invention consist of compositions comprise the covalent fusion of biomolecules, between this human papillomavirus antigens (HPV) to these CPP for induce a potent immune cellular responses against HPV and HPV protein antigen-exhibiting cells including HPV-associated tumors. The referred compositions are applicable in the pharmaceutical industry as vaccine for therapeutic use in human.Type: GrantFiled: July 31, 2008Date of Patent: March 18, 2014Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Isis del Carmen Torrens Madrazo, Maribel Guerra Vallespi, Milaid Granadillo Rodriguez, Osvaldo Reyes Acosta, Boris Ernesto Acevedo Castro
-
Publication number: 20130224313Abstract: This invention describes a method for treating cancer by increasing the nuclear localization of the COMMD1 protein, which is associated with decreasing or blocking the proliferation of the cancer cell. The invention is also related to the use of agents that increase nuclear localization of the COMMD1 protein, in the manufacture of a medicament for cancer therapy. These agents can be peptides or proteins, among other compounds. The invention is also related to the optimization of a peptide, coming from the sequence HARIKPTFRRLKWKKYKGKFW, to increase the nuclear localization of the protein COMMD, and thus, to increase the antitumor effect of this peptide.Type: ApplicationFiled: May 31, 2011Publication date: August 29, 2013Applicant: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Maribel Guerra Vallespi, Julio Raúl Fernández Massó, Alexis Musacchio Lasa, Jeovanis Gil Valdés, Osvaldo Reyes Acosta, Brizaida Maylin Oliva Argüelles
-
Publication number: 20130130971Abstract: The present invention describes a method to inhibit replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, more precisely the proteins forming the intermediate cytoskeletal filaments, wherein the said proteins are vimentin and/or keratin-10. The replication of the virus is inhibited in human cells by intervening in the structure of these proteins. The present invention is also related to the use of agents, which comprise peptides and/or interfering RNA and/or lipidic compounds, said agents producing a negative modulation or alteration of the cytoskeleton to prevent or to treat the HIV infection. The invention provides means and methods for altering the cytoskeleton/filament structure of cells, as a result of which the infection of human cells by HIV is disturbed and can even be completely inhibited. The cytoskeleton is altered by reducing the amount of vimentin and/or keratin (e.g.Type: ApplicationFiled: April 1, 2011Publication date: May 23, 2013Applicant: CENTRO DE INGENIERÁA GENÁTICA Y BIOTECNOLOGÁAInventors: Celia Berta Fernandez Ortega, Anna Caridys Ramírez Suárez, Dionne Casillas Casanova, Taimi Emelia Paneque Guerrero, Raimundo Ubieta Gómez, Marta Dubed Echevarria, Leonor Margarita Navea Leyva, Lila Rosa Castellanos Serra, Carlos Antonio Duarte Cano, Viviana Falcón Cama, Osvaldo Reyes Acosta
-
Patent number: 8431524Abstract: The present invention is related to the field of molecular immunology, particularly to a peptide derived from the sequence of interleukine-15 (IL-15), wherein said peptide was optimized to inhibit the biological activity of this molecule. In the present invention, it is shown that this peptide inhibits IL-15-induced T cell proliferation, Tumor Necrosis Factor ? (TNF?) induction and the expression of IL-8 and IL-6 by the IL-15 receptor ? subunit (IL-15R?), all these effects mediated by the binding of the peptide to the IL-15R?. The invention is also related to the use of the peptide to treat pathologies where the abnormal expression of IL-15 or IL-15R? is related to the course of the disease, such as rheumatoid arthritis (RA) and prostate cancer.Type: GrantFiled: September 30, 2009Date of Patent: April 30, 2013Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Alicia Santos Savio, Osvaldo Reyes Acosta, Haydee Geronimo Perez, Hilda Elisa Garay Perez, Yunier Rodriguez Alvarez, Gerardo Enríque Guillen Nieto
-
Patent number: 8420311Abstract: The present invention is related to a method for blocking the infection of cells by dengue virus, based on interfering the direct interaction of the viral envelope protein with a cellular receptor or its indirect interaction with said cellular receptor through a carrier protein, as well as related uses; wherein said cellular receptor is the alpha-2 macroglobulin receptor, also known as the low density receptor-related protein or as CD91, and said carrier protein is human alpha-2 macroglobulin.Type: GrantFiled: April 26, 2007Date of Patent: April 16, 2013Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Vivian Huerta Galindo, Glay Chinea Santiago, Noralvis Fleitas Salazar, Alejandro Miguel Martin Dunn, Monica Sarria Nunez, Osmany Guirola Cruz, Patricia Gabriela Toledo Mayora, Aniel Sanchez Puente, Vladimir Armando Besada Perez, Osvaldo Reyes Acosta, Hilda Elisa Garay Perez, Ania Cabrales Rico, Alexis Musacchio Lasa, Gabriel Ramon Padron Palomares, Luis Javier Gonzalez Lopez